Noted for handling the full spectrum of issues within the healthcare and life sciences sectors, Bär & Karrer Ltd. stands out for handling supply chain and licensing issues, in addition to contentious reimbursement and compliance work. Markus Schott is well-known for his expertise in public procurement and administrative proceedings within the pharma and medical device spaces. Markus Wang leads the firm’s IP practice, often advising on drug distribution and promotion, on top of acting in major patent disputes. Commercial litigation expert Oliver M. Brupbacher is a key name for investigations. Djamila Batache and Christine Schweikard are key figures within the team known for their IP and regulatory expertise respectively. Claudia Götz Staehelin left the firm in March 2025.

Homburger houses a broad offering which often advises on cross-border merger control, financing, and patent enforcement mandates. The team notably assists Novartis, Biocorp Holding, and Catalent. Daniel Häusermann stands out due to his broad experience in equity capital markets transactions, and both public and private M&A, while Andri Hess often assists clients with patent litigation and contractual IP issues. Richard Stäuber is well-known for his vast knowledge of merger control and competition investigation issues, with a strong focus on distribution arrangements.

Claudio Helmle, Jörg von Manger-Koenig, and Nicolas Mosimann jointly lead the team at Kellerhals Carrard, which is recommended for its expertise in SPC issues and pricing matters. Bern’s Helmle is particularly active across the biotech and pharma industries, often advising on reimbursement and authorisation matters, while von Manger-Koenig utilises his longstanding experience to advise on corporate issues within the sector. Thomas Eichenberger is noted for his vast knowledge of the rules surrounding the advertising and authorisation of medicinal products. In Basel, Mosimann is well-versed in M&A, R&D, and licence agreement work, often representing start-ups. Promoted to partner in January 2024, Virginie Rodieux is a key name for tech transfer and R&D contracts, and works out of the Lausanne office.

Divided between Zurich and Basel and described by clients as having the ‘best reputation for driving biotech deals in Switzerland’, VISCHER‘s broad offering spans the full range of corporate issues within the life sciences space, in addition to acting in administrative disputes concerning reimbursement and distribution issues. Stefan Kohler leads the team alongside the ‘outstanding’ Matthias Staehelin. Kohler is a key name for licensing and R&D agreements, in addition to handling both administrative and patent disputes. Staehelin is recommended for his deep knowledge of series financing and fundraising issues, often advising investors and major biotech companies and investors. Christian Wyss is particularly adept at advising on licence terms, and remains a key contact for start-ups, while Vincent Reardon utilises his broad corporate expertise to assist with M&As and IPOs.

Standing out due to its corporate and regulatory capabilities, Bratschi Ltd notably advises care providers, pharmacies, and major pharma companies. Praised by clients for his ‘intelligence and quick-mindedness’, Felix Kesselring leads the team from the Zurich office, and is recommended for his vast regulatory knowledge surrounding medical and pharmaceutical law, often appearing before administrative authorities. Yaël Heymann‘s area of expertise lies at the intersection between pharma and data protection law, with a strong focus on regulatory data protection work within the healthcare space.

Lenz & Staehelin‘s ‘technically brilliant’ team is well-equipped to handle the full gamut of issues arising across the biotech, medical device, diagnostics, and pharma industries. Zurich’s Thierry Calame is hailed by clients as an ‘adept and careful litigator’, and is well-known for his strength in unfair competition and copyright litigation, with a strong emphasis on IP-focused arbitrations, and disputes specialist Harold Frey routinely acts in international arbitrations and domestic proceedings involving joint ventures and licensing issues. In the Geneva office, Xavier Favre-Bulle is noted for his longstanding expertise in arbitrations concerning licences and post M&A issues, while Andreas Rötheli, who also leads the firm’s corporate and M&A group, often advises on private equity buyouts and real estate transactions.

Noted for its strength in life sciences IP work, MLL Legal regularly acts for major pharma companies, medical device clients, and universities. Nicola Benz leads the team alongside the ‘excellent’ Simon Holzer, who is recognised for his deep knowledge of IP litigation within the pharma industry, and is noted for his experience in regulatory work. European patent attorney Ulrike Ciesla is known for her vast expertise in both contentious and non-contentious pharma patent work. Louisa Galbraith routinely appears before the Swiss Federal Administrative Court in cases concerning pricing orders from the Federal Office of Public Health, and appeals against Swissmedic decisions.

Franz Schubiger, Lara Dorigo, and Christian Roos jointly lead the Zurich-based team at Pestalozzi, which is well-placed to assist with collaboration agreements, the financing of research projects, and the full range of issues relating to distribution and licensing. Schubiger is a key contact for financial investors, SMEs, and major corporations across the biotech and pharma spaces. Dorigo routinely acts in patent litigation involving biologics and medtech products, while Roos handles the employment aspects of M&A and corporate restructurings. Sarah Drukarch regularly advises on major R&D projects and marketing authorisations, and Alexandra Bühlmann is particularly adept at handling unfair competition mandates.

The offering at Schellenberg Wittmer Ltd covers a varied workload, with a strong emphasis on M&A, spin-offs, and product liability disputes. The team is also recommended for assisting with allegations of abuse of dominant position and private equity transactions within the healthcare space. Practice co-head Philipp Groz is particularly adept at handling international arbitrations concerning distribution, development, and supply agreements, often representing pharma companies; Groz is also noted for his regulatory expertise in mobile health apps. ‘Top notch IP practitioner’ Lorenza Ferrari Hofer co-leads the team, and is recommended for her strong focus on cross-border licensing and distribution issues relating to tech and health products, in addition to acting in trade secret and patent infringement disputes. Peter Georg Picht‘s area of expertise lies at the intersection between IP and competition law on a domestic and European level.

Hailed as the ‘best pharma regulatory team in Switzerland’, Walder Wyss Ltd. houses a broad offering which acts on both contentious and non-contentious pricing-focused mandates, hospital planning proceedings, and strategic collaboration agreements. Michael Isler leads the team alongside Andreas Wildi, who stands out due to his vast knowledge of domestic and international reimbursement and pricing issues surrounding medical devices, and pharmaceutical and blood products. Key members of the team include Annemarie Lagger, who is particularly adept at handling supply chain and market access issues, and Celine Weber, who is recommended for her expertise in pharma advertising work.

Wenger Plattner regularly handles corporate and commercial issues for pharma clients, including the financing of research projects. In Basel, practice head Tobias Meili is well-versed in corporate governance issues and M&A within the life sciences space, while Carlo Conti combines his broad experience of administrative and pharma law to advise on market authorisations. Daniel Zimmerli joined the firm in March 2024 from Walder Wyss Ltd., bringing his expertise in hospital planning matters.

Leveraging its international network of offices, Baker McKenzie Switzerland AG assists a high-profile client roster of major pharma and biotech corporations, including Sino Biopharmaceutical, Baxter, and Bristol Myers Squibb. Jointly leading the practice, Geneva’s Olha Demianiuk is recommended for her expertise in healthcare product portfolio acquisitions, corporate reorganisations, and regulatory compliance, and Julia Schieber stands out due to her strong focus on commercial transactions concerning the supply and distribution of pharma, biotech, and medical device products in the Zurich office.

The team at Valfor Attorneys-at-law is known for its strong focus on mandates concerning the management of public healthcare facilities and the financing of healthcare services. The team is also noted for handling public procurement issues. Practice co-lead Marc Metzger has longstanding expertise in corporate and commercial issues with a strong focus on distribution agreements and public procurement, while co-head Christophe De Kalbermatten is noted for his experience in M&A and insolvency. Stipe Jozic often advises on joint ventures and corporate restructuring work.

CMS von Erlach Partners Ltd. houses a broad offering which notably acts for Bayer, Eli Lilly, and Unilabs, often leveraging its international network of offices. The team also handles advertising-focused proceedings and cross-border acquisitions. Team co-leads Patrick Sommer routinely advises on M&A and administrative proceedings concerning antitrust pricing issues, and Christoph Willi is well-equipped to handle series financing matters and patent portfolio management mandates.

The broad offering at MME Legal | Tax | Compliance is well-equipped to assist with private equity investments into healthcare bodies, medical cannabis licensing matters, and transfer pricing work. Jonatan Baier leads the team with his longstanding experience in administrative procedures and contractual issues relating to distribution, joint ventures, and collaborations. Daniel Haymann is recommended for his strong focus on psychedelic and cannabinoid regulatory issues within the healthcare space, in addition to his handling of financing transactions.

Niederer Kraft Frey AG assists clients with the full range of corporate and regulatory matters, acting for diagnostics, medtech, and biotech corporations. Promoted to partner in January 2024, ‘outstanding lawyer and attorney’ Janine Reudt-Demont co-leads the team and is recommended for her deep regulatory knowledge, particularly in relation to advertising and data protection within the pharma and medical device industries. Co-head Philipp Haas is well-equipped to assist with public M&A and takeovers.

Praised by clients for providing ‘best in class service’, Sidley Austin LLP handles the full gamut of issues relating to early access programs and disputes with insurers regarding pricing. Having assumed leadership of the team in January 2024, Eva von Mühlenen is noted for her vast experience in digital health work involving AI, in addition to product certification and manufacturing practices.

Wenger Vieli Ltd is well-equipped to assist with mandates concerning the de-listing of reimbursed products, M&A, and product liability claims. Frank Scherrer leads the team with his longstanding expertise in establishment licences, marketing authorisations, and data protection issues. Marcel Boller is a key contact for pharma companies and pharmacies seeking advice on data exclusivity issues and joint ventures.